Chan Henry Lee Sells 332 Shares of BeOne Medicines (NASDAQ:ONC) Stock

Posted by Brenda Bartman on May 17th, 2026

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) SVP Chan Henry Lee sold 332 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $310.72, for a total value of $103,159.04. Following the completion of the sale, the senior vice president owned 101 shares of the company’s stock, valued at approximately $31,382.72. This represents a 76.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $311.59, for a total value of $103,447.88.
On Wednesday, March 11th, Chan Henry Lee sold 341 shares of BeOne Medicines stock. The shares were sold at an average price of $300.00, for a total value of $102,300.00.

BeOne Medicines Stock Performance

Shares of ONC opened at $293.27 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The stock has a 50-day moving average of $300.41 and a 200-day moving average of $321.73. The company has a market cap of $32.18 billion, a PE ratio of 65.61 and a beta of 0.50. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $227.05 and a one year high of $385.22.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last issued its earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The company had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. On average, equities research analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 EPS for the current fiscal year.

Hedge Funds Weigh In On BeOne Medicines

Several large investors have recently added to or reduced their stakes in ONC. Quantinno Capital Management LP lifted its position in shares of BeOne Medicines by 24.2% during the 1st quarter. Quantinno Capital Management LP now owns 8,312 shares of the company’s stock worth $2,469,000 after buying an additional 1,622 shares in the last quarter. Lazard Asset Management LLC lifted its position in shares of BeOne Medicines by 30.5% during the 1st quarter. Lazard Asset Management LLC now owns 62,917 shares of the company’s stock worth $18,684,000 after buying an additional 14,696 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of BeOne Medicines during the 1st quarter worth approximately $19,438,000. Arrowstreet Capital Limited Partnership lifted its position in shares of BeOne Medicines by 96.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 110,586 shares of the company’s stock worth $32,841,000 after buying an additional 54,260 shares in the last quarter. Finally, First Trust Advisors LP lifted its position in shares of BeOne Medicines by 91.9% during the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after buying an additional 115,601 shares in the last quarter. Institutional investors own 48.55% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on ONC shares. Guggenheim raised their price target on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Truist Financial reaffirmed a “buy” rating and issued a $413.00 price target (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Morgan Stanley reaffirmed an “overweight” rating and issued a $395.00 price target on shares of BeOne Medicines in a research report on Thursday, May 7th. Finally, Barclays raised their price target on shares of BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, BeOne Medicines currently has a consensus rating of “Moderate Buy” and an average target price of $389.15.

Check Out Our Latest Analysis on BeOne Medicines

BeOne Medicines Company Profile

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.